Developer docs
API playgroundTry for free, no card

Search company profiles

Sirakoss

Full company profile

uuid000ceov

Namestring
Sirakoss
Legal namestring
OssDsign AB
Websiteurl
sirakoss.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Sirakoss is a Scotland-based medical device company founded in 2010 that developed a proprietary nanosynthetic, silicate-substituted calcium phosphate bone graft substitute. Its core technical differentiator is the direct substitution of silicate ions into the graft's calcium phosphate chemistry—rather than surface coating or carrier-based delivery—which provides sustained silicate signaling and activates a dual-pathway healing mechanism combining endochondral ossification with intramembranous bone formation. The product is now commercialized worldwide as OssDsign Catalyst, an off-the-shelf putty available in 1cc, 2.5cc, 5cc, and 10cc sizes, and is the first synthetic bone graft cleared by the FDA for use in spinal interbody fusions based on bone graft data alone.

In November 2020 Sirakoss was acquired by OssDsign AB (Nasdaq First North: OSSD; headquartered in Uppsala, Sweden) and now operates as a wholly-owned subsidiary. Following the acquisition, OssDsign discontinued its legacy patient-specific cranial implant business (OssDsign Cranial PSI) at the end of December 2023 to become a pure-play orthobiologics company focused on Catalyst. The technology is supported by the TOP FUSION first-in-human clinical study and the ongoing PROPEL Spine Registry—a multi-center, prospective study that has enrolled 365 patients across 15 sites in the U.S.—with reported 93% fusion rates within 12 months even in complex multi-level spinal surgeries.

The business model is direct B2B sale of a single Class-equivalent hardware product to hospitals, ambulatory surgical centers, and spine/orthopedic surgeons, primarily in the U.S. market (with presence in the UK, Germany, and Sweden). Commercial channels are concentrated on field sales supported by KOL engagement, clinical evidence publication, surgeon testimonials, and participation in major spine and orthopedic congresses (NASS, SMISS, AOFAS, etc.). Pricing is quote-based and not publicly disclosed; the parent has historically characterized the orthobiologics business as high gross margin and high scalability, and its major shareholders are predominantly Nordic institutional investors (Avania Pension 10.6%, Linc AB 10.0%, TAMT AB 8.1%, FSG Fund 7.2%).

Short descriptiontext

Sirakoss is a Scotland-based medical device company that developed the proprietary silicate-substituted nanosynthetic bone graft technology now commercialized as OssDsign Catalyst. Acquired by OssDsign AB in November 2020, it operates as a wholly-owned subsidiary serving spine and orthopedic surgeons.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic bone grafts, orthobiologics products, bone graft substitutes, spinal fusion materials, calcium phosphate grafts
Industry2 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthobiologics / Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales - Bone Graft Products
TypeHardware Sales
Description

Revenue generated from the sale of OssDsign Catalyst nanosynthetic bone graft products to hospitals and surgical centers. Products are sold directly to healthcare providers for use in spinal fusion and orthopedic surgical procedures. The company characterizes its orthobiologics business as having high gross margins and high scalability.

sirakoss.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OssDsign Catalyst
Description

Nanosynthetic, silicate-substituted bone graft designed for spinal fusion and bone healing applications. The flagship orthobiologics product of the company.

sirakoss.com
+1 more record
Core offering1 text field

Sirakoss developed a next-generation nanosynthetic bone graft substitute designed to provide surgeons an easy-to-use and effective solution for treating skeletal defects with many applications including spinal fusion surgery. The technology is a silicate-substituted calcium phosphate synthetic bone graft with a dual-pathway healing mechanism. Following acquisition by OssDsign AB in November 2020, the technology has been commercialized as OssDsign Catalyst.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 93% fusion rates within 12 months in complex multi-level spinal surgeries
+2 more records
Product overview1 text field

OssDsign is a developer and global provider of next generation orthobiologics products. The company's product portfolio centers on OssDsign Catalyst, a nanosynthetic bone graft substitute designed for spinal fusion and bone healing applications. Following a September 2023 strategic shift, the company discontinued its patient-specific cranial implant business (OssDsign Cranial PSI) to become a pure-play orthobiologics company focused on the off-the-shelf Catalyst product. The company also conducts clinical studies including PROPEL Spine Registry and TOP FUSION to generate real-world evidence for Catalyst's performance.

Product and service1 record
1Sirakoss Nanosynthetic Bone Graft Substitute (OssDsign Catalyst)
CategoryOrthobiologics / Bone graft substitute
Description

A next-generation nanosynthetic, silicate-substituted calcium phosphate bone graft substitute designed for spinal fusion and bone healing applications, with a dual-pathway healing mechanism (endochondral ossification and intramembranous bone formation) and cell-mediated coupled remodeling. Targets spine surgeons, orthopedic surgeons, and hospitals for use in interbody fusion, cervical/thoracic/lumbar fusion, deformity correction, and extremity procedures.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Sirakoss Ltd
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in November 2020, Sirakoss Ltd developed the OssDsign Catalyst nanosynthetic bone graft technology. This acquisition expanded OssDsign from cranial implants into orthobiologics. Tom Buckland, CTO, previously served as CEO of SIRAKOSS Ltd.

sirakoss.com
Strategic tierCoreTypeOthers
Description

Registered audit firm elected at Annual General Meeting 2022. Oskar Wall is Chief Auditor.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spine surgery specialist with biologic bone graft products that compete head-to-head in spinal fusion with OssDsign Catalyst; the CTO of OssDsign was previously Managing Director of NuVasive UK.

TypeDirect peer
Description

Spine-focused pure-play with broad orthobiologics portfolio (including DBM, allograft, synthetic bone grafts) directly comparable to OssDsign Catalyst in spinal fusion applications.

TypeDirect peer
Description

Pure-play orthobiologics company commercialising i-FACTOR peptide-enhanced bone graft for cervical spine fusion, a direct competitor in FDA-cleared biologic bone graft substitutes.

TypeDirect peer
Description

Pure-play orthobiologics company focused on bone graft substitutes and sports medicine, a small-cap comparable in scale and product breadth to OssDsign.

5Bone Biologics
TypeDirect peer
Description

Orthobiologics R&D-stage company developing recombinant protein bone graft (NELL-1/DBM) for spinal fusion; broadly comparable technology category and end market.

TypeBroad incumbent
Description

Dominant spine + biologics incumbent selling INFUSE rhBMP-2 bone graft and integrated hardware kits; the broader platform that OssDsign must dislodge in spinal fusion.

TypeBroad incumbent
Description

Large diversified orthopedics player offering bone graft substitutes (e.g., Vitoss, Bio4) as part of broader spine and extremities portfolios; competes with Catalyst in trauma and extremity indications.

TypeBroad incumbent
Description

Holds the legacy ApaTech orthobiologics franchise where multiple OssDsign executives previously worked (CTO Tom Buckland co-founded ApaTech, VP Clinical Melanie Marshall was VP Clinical at ApaTech).

TypeBroad incumbent
Description

Orthobiologics-focused public company providing bone graft substitutes and osteoarthritis pain treatments, comparable commercial-stage orthobiologics platform.

TypeEmerging player
Description

European-listed orthobiologics company commercialising antibiotic-loaded and synthetic bone graft technologies (CERAMENT); comparable pure-play/orthobiologics profile, peer for a public-listed synthetic bone graft company.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sirakoss

Orthobiologics / Medical Devicessirakoss.com

Sirakoss is a Scotland-based medical device company that developed the proprietary silicate-substituted nanosynthetic bone graft technology now commercialized as OssDsign Catalyst. Acquired by OssDsign AB in November 2020, it operates as a wholly-owned subsidiary serving spine and orthopedic surgeons.

What Sirakoss does

Sirakoss is a Scotland-based medical device company founded in 2010 that developed a proprietary nanosynthetic, silicate-substituted calcium phosphate bone graft substitute. Its core technical differentiator is the direct substitution of silicate ions into the graft's calcium phosphate chemistry—rather than surface coating or carrier-based delivery—which provides sustained silicate signaling and activates a dual-pathway healing mechanism combining endochondral ossification with intramembranous bone formation. The product is now commercialized worldwide as OssDsign Catalyst, an off-the-shelf putty available in 1cc, 2.5cc, 5cc, and 10cc sizes, and is the first synthetic bone graft cleared by the FDA for use in spinal interbody fusions based on bone graft data alone.

In November 2020 Sirakoss was acquired by OssDsign AB (Nasdaq First North: OSSD; headquartered in Uppsala, Sweden) and now operates as a wholly-owned subsidiary. Following the acquisition, OssDsign discontinued its legacy patient-specific cranial implant business (OssDsign Cranial PSI) at the end of December 2023 to become a pure-play orthobiologics company focused on Catalyst. The technology is supported by the TOP FUSION first-in-human clinical study and the ongoing PROPEL Spine Registry—a multi-center, prospective study that has enrolled 365 patients across 15 sites in the U.S.—with reported 93% fusion rates within 12 months even in complex multi-level spinal surgeries.

The business model is direct B2B sale of a single Class-equivalent hardware product to hospitals, ambulatory surgical centers, and spine/orthopedic surgeons, primarily in the U.S. market (with presence in the UK, Germany, and Sweden). Commercial channels are concentrated on field sales supported by KOL engagement, clinical evidence publication, surgeon testimonials, and participation in major spine and orthopedic congresses (NASS, SMISS, AOFAS, etc.). Pricing is quote-based and not publicly disclosed; the parent has historically characterized the orthobiologics business as high gross margin and high scalability, and its major shareholders are predominantly Nordic institutional investors (Avania Pension 10.6%, Linc AB 10.0%, TAMT AB 8.1%, FSG Fund 7.2%).

Sirakoss firmographics

Firmographics
Name
Sirakoss
Legal name
OssDsign AB
Website
https://sirakoss.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Sirakoss is a Scotland-based medical device company that developed the proprietary silicate-substituted nanosynthetic bone graft technology now commercialized as OssDsign Catalyst. Acquired by OssDsign AB in November 2020, it operates as a wholly-owned subsidiary serving spine and orthopedic surgeons.
Ownership category
akta.pro rank

Sirakoss industry classification

Industry
Product category
Orthobiologics / Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Synthetic bone grafts
  • Orthobiologics products
  • Bone graft substitutes
  • Spinal fusion materials
  • Calcium phosphate grafts

Where Sirakoss is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Sirakoss business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Medical Device Sales - Bone Graft Products: Revenue generated from the sale of OssDsign Catalyst nanosynthetic bone graft products to hospitals and surgical centers. Products are sold directly to healthcare providers for use in spinal fusion and orthopedic surgical procedures. The company characterizes its orthobiologics business as having high gross margins and high scalability.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Sirakoss product offering

Product offering

Core offering

Sirakoss developed a next-generation nanosynthetic bone graft substitute designed to provide surgeons an easy-to-use and effective solution for treating skeletal defects with many applications including spinal fusion surgery. The technology is a silicate-substituted calcium phosphate synthetic bone graft with a dual-pathway healing mechanism. Following acquisition by OssDsign AB in November 2020, the technology has been commercialized as OssDsign Catalyst.

Product overview

OssDsign is a developer and global provider of next generation orthobiologics products. The company's product portfolio centers on OssDsign Catalyst, a nanosynthetic bone graft substitute designed for spinal fusion and bone healing applications. Following a September 2023 strategic shift, the company discontinued its patient-specific cranial implant business (OssDsign Cranial PSI) to become a pure-play orthobiologics company focused on the off-the-shelf Catalyst product. The company also conducts clinical studies including PROPEL Spine Registry and TOP FUSION to generate real-world evidence for Catalyst's performance.

Differentiator

Problem solved

Functional benefit

Brands

  • OssDsign Catalyst: Nanosynthetic, silicate-substituted bone graft designed for spinal fusion and bone healing applications. The flagship orthobiologics product of the company.
  • OssDsign Cranial PSI

Products and services

  • Sirakoss Nanosynthetic Bone Graft Substitute (OssDsign Catalyst) A next-generation nanosynthetic, silicate-substituted calcium phosphate bone graft substitute designed for spinal fusion and bone healing applications, with a dual-pathway healing mechanism (endochondral ossification and intramembranous bone formation) and cell-mediated coupled remodeling. Targets spine surgeons, orthopedic surgeons, and hospitals for use in interbody fusion, cervical/thoracic/lumbar fusion, deformity correction, and extremity procedures.

Quantifiable outcome

  • 93% fusion rates within 12 months in complex multi-level spinal surgeries
  • +2 more outcomes

Companies that use Sirakoss

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Sirakoss technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sirakoss partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Sirakoss LtdcoreStrategic or Co-development PartnerAcquired in November 2020, Sirakoss Ltd developed the OssDsign Catalyst nanosynthetic bone graft technology. This acquisition expanded OssDsign from cranial implants into orthobiologics. Tom Buckland, CTO, previously served as CEO of SIRAKOSS Ltd.
  • Ernst & Young ABcoreOthersRegistered audit firm elected at Annual General Meeting 2022. Oskar Wall is Chief Auditor.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Sirakoss competitors and assessment

Company assessment

Direct peers

  • NuVasive (now part of Globus Medical): Spine surgery specialist with biologic bone graft products that compete head-to-head in spinal fusion with OssDsign Catalyst; the CTO of OssDsign was previously Managing Director of NuVasive UK.
  • SeaSpine (now Orthofix Medical): Spine-focused pure-play with broad orthobiologics portfolio (including DBM, allograft, synthetic bone grafts) directly comparable to OssDsign Catalyst in spinal fusion applications.
  • Cerapedics: Pure-play orthobiologics company commercialising i-FACTOR peptide-enhanced bone graft for cervical spine fusion, a direct competitor in FDA-cleared biologic bone graft substitutes.
  • Xtant Medical: Pure-play orthobiologics company focused on bone graft substitutes and sports medicine, a small-cap comparable in scale and product breadth to OssDsign.
  • Bone Biologics: Orthobiologics R&D-stage company developing recombinant protein bone graft (NELL-1/DBM) for spinal fusion; broadly comparable technology category and end market.

Broad incumbents

  • Medtronic (Sofamor Danek): Dominant spine + biologics incumbent selling INFUSE rhBMP-2 bone graft and integrated hardware kits; the broader platform that OssDsign must dislodge in spinal fusion.
  • Stryker: Large diversified orthopedics player offering bone graft substitutes (e.g., Vitoss, Bio4) as part of broader spine and extremities portfolios; competes with Catalyst in trauma and extremity indications.
  • Baxter International: Holds the legacy ApaTech orthobiologics franchise where multiple OssDsign executives previously worked (CTO Tom Buckland co-founded ApaTech, VP Clinical Melanie Marshall was VP Clinical at ApaTech).
  • Bioventus: Orthobiologics-focused public company providing bone graft substitutes and osteoarthritis pain treatments, comparable commercial-stage orthobiologics platform.

Emerging players

  • Bonesupport: European-listed orthobiologics company commercialising antibiotic-loaded and synthetic bone graft technologies (CERAMENT); comparable pure-play/orthobiologics profile, peer for a public-listed synthetic bone graft company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Sirakoss social profiles

Digital presence

Sirakoss financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sirakoss leadership team

Management profile

Number of profiles

Profiles1 record

Sirakoss subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Sirakoss funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sirakoss M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirakoss

What does Sirakoss do?

Sirakoss developed a next-generation nanosynthetic bone graft substitute designed to provide surgeons an easy-to-use and effective solution for treating skeletal defects with many applications including spinal fusion surgery. The technology is a silicate-substituted calcium phosphate synthetic bone graft with a dual-pathway healing mechanism. Following acquisition by OssDsign AB in November 2020, the technology has been commercialized as OssDsign Catalyst.

Is Sirakoss a public or private company?

Sirakoss is a public company. It is classified as corporate owned and is currently operating.

When was Sirakoss founded?

Sirakoss was founded in 2011. It employs 1 to 10 people.

Where is Sirakoss based?

Sirakoss is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does Sirakoss make money?

One revenue line is on record: medical Device Sales - Bone Graft Products.

Who are Sirakoss's main competitors?

Direct peers on record are NuVasive (now part of Globus Medical), SeaSpine (now Orthofix Medical), Cerapedics, Xtant Medical and Bone Biologics. Broad incumbents are Medtronic (Sofamor Danek), Stryker, Baxter International and Bioventus. Bonesupport is listed as an emerging player.

Does Sirakoss have an API?

No public API is recorded for Sirakoss.

What industry is Sirakoss in?

Sirakoss's product category is Orthobiologics / Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comOssDsign to present Sirakoss acquisition via live WebcastOssDsign will host a live webcast on November 4th to present its acquisition of Sirakoss Ltd. CEO Morten Henneveld will lead the presentation, with the webcast available via a provided link. The company, a Swedish medical technology firm, develops regenerative implants for cranial and facial defects.GlobeNewswireKarolinska Development's portfolio company OssDsign enters USD 4 billion bone graft market by acquiring Sirakoss LtdOssDsign acquired Sirakoss Ltd, a bone graft substitute company, in an all-cash deal for USD 11 million. The acquisition is partly financed by a directed share issue of about SEK 65 million, and OssDsign expects revenue from the product in the second half of 2021.UnquoteEpidarex sells Sirakoss to VC-backed OssDsignSirakoss, a UK medical device firm, was acquired by VC-backed OssDsign for $11m in cash plus milestone and royalty payments. The deal adds Sirakoss's synthetic bone-graft product to OssDsign's craniomaxillofacial portfolio, with US commercial activities expected to begin immediately.news.cision.comOssDsign announces intention to carry out a directed share issue as part of the financing of the acquisition of SirakossOssDsign announced a directed share issue of about SEK 55 million to fund its acquisition of Sirakoss, a bone graft substitute company. The issue will be priced via accelerated book building, with results expected before trading on Nasdaq First North Growth Market on November 4, 2020.news.cision.comOssDsign – strong sales in third quarter 2020OssDsign reported Q3 2020 net sales of TSEK 6,481, up 39% year-over-year, and a loss of TSEK 18,740. The company also announced an agreement to acquire Sirakoss and plans a directed share issue to finance the acquisition.news.cision.comOssDsign acquires Sirakoss, enters USD 4 billion bone graft marketOssDsign acquired Sirakoss, a Scottish bone graft specialist, in an all-cash deal for $11 million, subject to closing conditions. The purchase includes Sirakoss's FDA-cleared Osteo3 ZP Putty, a synthetic bone graft substitute, and expands OssDsign's addressable market five times. Commercial activities in the US spinal fusion market are expected to generate revenue in the second half of 2021.The Daily RecordEpidarex Capital acquires Sirakoss by OssDsignEpidarex Capital has acquired Sirakoss by OssDsign, a Swedish medtech company, for $11 million plus milestone and royalty payments. The acquisition follows the recent FDA 510(k) marketing clearance for Sirakoss's Osteo3 ZP Putty, a nanosynthetic bone graft substitute, with US commercial activities expected to begin immediately.PR NewswireEpidarex Capital Portfolio Company Sirakoss Acquired By OssdsignSwedish medtech company OssDsign has acquired Sirakoss, a portfolio company of transatlantic life science venture firm Epidarex Capital, for an initial cash consideration of USD 11 million plus potential milestone and royalty payments. Sirakoss has developed Osteo3 ZP Putty, a nanosynthetic bone graft substitute that recently received 510(k) marketing clearance from the US FDA for spine and trauma bone grafting procedures. Commercial activities for the product in the US are expected to begin immediately, complementing OssDsign's craniomaxillofacial portfolio.BioWorldSirakoss scores FDA nod for nanoparticle synthetic bone graft substituteSirakoss Ltd. received FDA 510(k) clearance for its nanoparticle synthetic bone graft substitute, Osteo3 Zp putty. The ready-to-use putty is equivalent to the CE-approved dry formulation, with granules suspended in a synthetic resorbable carrier rather than mixed with blood.RyorthoSIRAKOSS: Two New Bone Graft PatentsSIRAKOSS Ltd., a UK-based company, announced that the USPTO granted two patents for its bone graft technologies. The patents cover novel putty formulations and microstructural properties, with the company's synthetic technology containing no human tissue. The patents endorse the company's core belief in its differentiated product chemistry and manufacturing method.